CURE’s breast cancer page is an extensive resource of cancer information featuring the latest breast cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on breast cancer.
September 27th 2024
As a caregiver to my daughter who had breast cancer, pink takes on a new meaning for us — one I’m not quite a fan of.
September 25th 2024
September 23rd 2024
September 18th 2024
Dose-Dense Chemotherapy Improves Disease-Free Survival in HR+/HER2- Breast Cancer
October 13th 2020Researchers found that neoadjuvant chemotherapy with intense dose-dense Ellence (epirubicin), Taxol (paclitaxel), and Cytoxan (cyclophosphamide) (iddEPC) demonstrated significant disease-free survival benefits in the treatment of patients with HR+/HER2- breast cancer.
Tecentriq Combo Improves Response Rates in Early TNBC, Regardless of PD-L1 Status
September 22nd 2020Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast cancer significantly improved pathologic complete responses, compared with placebo plus chemotherapy.
Paclitaxel, Carboplatin Regimen Shows Promise in Triple-Negative Breast Cancer
September 17th 2020“This randomized clinical trial found that compared with the conventional anthracycline and docetaxel regimen, the paclitaxel-plus-carboplatin regimen may be an alternative adjuvant chemotherapy strategy for patients with operable TNBC,” the authors wrote.
An Expert Explains the Three Major Treatment Modalities in Triple Negative Breast Cancer
September 15th 2020“In the field of triple-negative breast cancer, we're beginning to see some remarkable advances, mostly centering around the three paradigms that have become so attractive for the treatment of cancer: immunotherapy, targeted biologics and antibody-drug conjugates,” Dr. Howard A. “Skip” Burris, III said in an interview.
FDA Warns Tecentriq-Paclitaxel Combination Failed to Treat Locally Advanced or Metastatic TNBC
September 8th 2020The Food and Drug Administration’s warning comes weeks after Genentech, the manufacturer of Tecentriq, issued a press release noting that the IMpassion131 trial failed to meet its primary endpoint of improving progression-free survival in patients with triple-negative breast cancer.
Knowing Your Community of Patient Navigators
August 8th 2020Patient navigators are the vaunted “healthcare emissaries” for patients with breast cancer and can help navigate their journey a great deal. In this conversation from the Susan G. Komen Greater New York City “Empowering and Mobilizing Our Patient Navigation Workforce” virtual conference experts highlight the results of a survey of patient navigators.